Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Roche Glycart Ag

Jan Olaf Stracke

Ulrich Brinkmann

Rebecca Croasdale

Guy Georges

Olaf Mundigl

Werner Scheuer

Eike Hoffmann

Alexander Haas

Silke Metz

Joerg Thomas Regula

Wilma Dormeyer

Christian Klein

Paul Parren

Ekkehard Moessner

Pablo Umana

Erhard Kopetzki

Stefan Seeber

Jan Van De Winkel

Kay-Gunnar Stubenrauch

Peter Bruenker

Ralf Schumacher

Birgit Bramlage

Adelbert Grossmann

Yvo Graus

Juergen Michael Schanzer

Martin Lanzendoerfer

Frank Rebers

Friederike Hesse

Martine Van Vugt

Matthias John

Josef Endl

Apollon Papadimitriou

Kerstin Jahn-Hofmann

Ludger Ickenstein

Sebastian Neumann

Wilma Lau

Maria Elena Fuentes

Michael Grote

Simone Dill

Sandra Vereecken-Verploegen

Ludger Markus Ickenstein

The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent

The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Multispecific antibodies comprising full length antibodies and single chain fab fragments

This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Bi-specific digoxigenin binding antibodies

The instant specification discloses an antibody binding to IL-13R&#x3b1;1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.

Antibodies against IL-13 receptor alpha1 and uses thereof

A method for the production of the N-terminal four kringle-containing fragment of hepatocyte growth factor (NK4) by expression of a nucleic acid encoding said NK4 in a microbial host cell, isolation of inclusion bodies containing said NK4 in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK4, characterized in that solubilization and naturation are performed at pH 7-9 in phosphate buffered solution, provides NK4 in high purity and high yield.

Method for the purification of an N-terminal fragment of hepatocyte growth factor

Growing community of inventors

Munich, Germany

Jan Olaf Stracke